Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Malignant neoplasm of lung
|
1142 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.800 | 1.000 | 20 | 2010 | 2015 | |||||
Carcinoma of lung
|
1204 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.800 | 1.000 | 19 | 2010 | 2015 | |||||
Glioma
|
353 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.900 | 0.889 | 18 | 2009 | 2020 | |||||
Primary malignant neoplasm of lung
|
981 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.100 | 1.000 | 18 | 2010 | 2015 | |||||
Adenocarcinoma of lung (disorder)
|
563 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.880 | 1.000 | 11 | 2009 | 2016 | |||||
Adenocarcinoma
|
168 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.080 | 1.000 | 8 | 2009 | 2016 | |||||
Chronic myeloproliferative disorder
|
47 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.080 | 1.000 | 8 | 2014 | 2019 | |||||
Malignant Neoplasms
|
1641 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.070 | 1.000 | 7 | 2012 | 2018 | |||||
Neoplasms
|
1644 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.070 | 1.000 | 7 | 2010 | 2017 | |||||
Primary malignant neoplasm
|
1374 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.070 | 1.000 | 7 | 2012 | 2018 | |||||
Non-Small Cell Lung Carcinoma
|
712 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.060 | 1.000 | 6 | 2009 | 2016 | |||||
Central Nervous System Neoplasms
|
72 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.800 | 1.000 | 5 | 2009 | 2014 | |||||
Breast Carcinoma
|
2793 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.040 | 0.750 | 4 | 2015 | 2019 | |||||
Idiopathic Pulmonary Fibrosis
|
63 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.840 | 1.000 | 4 | 2008 | 2019 | |||||
Malignant neoplasm of breast
|
3417 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.040 | 0.750 | 4 | 2015 | 2019 | |||||
Myeloproliferative disease
|
43 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.040 | 1.000 | 4 | 2014 | 2016 | |||||
Thyroid carcinoma
|
145 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.040 | 1.000 | 4 | 2016 | 2019 | |||||
Colorectal Carcinoma
|
1962 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.030 | 0.667 | 3 | 2012 | 2015 | |||||
Malignant neoplasm of stomach
|
615 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.030 | 1.000 | 3 | 2015 | 2017 | |||||
Papillary thyroid carcinoma
|
204 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.030 | 1.000 | 3 | 2016 | 2019 | |||||
Polycythemia Vera
|
38 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.030 | 1.000 | 3 | 2015 | 2018 | |||||
Stomach Carcinoma
|
652 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.030 | 1.000 | 3 | 2015 | 2017 | |||||
Testicular Germ Cell Tumor
|
93 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.800 | 1.000 | 3 | 2013 | 2017 | |||||
Thrombocythemia, Essential
|
37 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.030 | 1.000 | 3 | 2015 | 2018 | |||||
Arteriosclerosis
|
267 | 0.550 | 0.880 | 5 | 1286401 | 3 prime UTR variant | C/A | snv | 0.52 | 0.020 | 1.000 | 2 | 2014 | 2015 |